Physician profile

Michelle Stanley

Psychiatric/Mental Health (Nurse Practitioner) · Ashburn, VA

NPI 1194326595

$440.33

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$191.83

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $189.11 2021-2024
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $92.26 2024 Caplyta
Vanda Pharmaceuticals INC. $44.90 2021
Avanir Pharmaceuticals, INC. $35.85 2022
Janssen Pharmaceuticals, INC $26.42 2021
Sunovion Pharmaceuticals INC. $22.00 2021
Jazz Pharmaceuticals INC. $15.44 2021
Alkermes, INC. $14.35 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michelle Stanley

$440.33

in general payments reported 2019-2025

Years
2021-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/10928046/michelle-stanley

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.